Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: We would like to point out that the IRC, which sponsored the study by Dr Kahn and colleagues,1 has been accused of previous attempts to improperly influence the presentation of scientific data on its HIV-1 Immunogen.
In June 1994, authors from the company published the results of a placebo-controlled trial of this agent. The authors concluded that the vaccine "may . . . stabilize the percent of CD4 cell decline."2
Lurie P, Wolfe SM. Outcomes of a Trial of HIV-1 Immunogen in Patients With HIV Infection. JAMA. 2001;285(17):2191-2195. doi:10.1001/jama.285.17.2191